PolyPid

PolyPid

Yahoo Finance • 10 days ago

PolyPid (PYPD) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 12, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer - Dikla Czaczkes Akselbrad Chief Financial Officer - Jonny Missulawin Chief Operating Officer, U.S. - Ori Warshavsky... Full story

Yahoo Finance • 17 days ago

PolyPid Q2 Earnings Call Highlights

Key Points Interested in PolyPid Ltd.? Here are five stocks we like better. FDA review advances: PolyPid's NDA for D-PLEX100 was accepted on July 27, 2026, with priority review and a Nov. 28 PDUFA target date. The company is preparing for... Full story

Yahoo Finance • last month

PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀

PDUFA target action date of November 28, 2026, approximately one quarter ahead of Company’s previously communicated guidance FDA identified no Filing review issues Acceptance triggers $15 million milestone payment, completing $30 million... Full story

Yahoo Finance • last month

PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada

PolyPid to potentially receive over $320 million in upfront and milestone payments, including $30 million in upfront and near-term milestone payments, plus tiered royalties ranging from mid-teen to mid-twenties percentagesAzurity, a privat... Full story

Yahoo Finance • 3 months ago

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

If approved, D-PLEX100 would address a critical unmet medical need in the prevention of surgical site infections PDUFA target action date currently planned for the first quarter of 2027 PETACH TIKVA, Israel, June 01, 2026 (GLOBE NEWSWI... Full story

Yahoo Finance • 9 months ago

PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

PETACH TIKVA, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a formal pre-New D... Full story

Yahoo Finance • 10 months ago

PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Face-to-Face Pre-NDA Meeting with the FDA Scheduled for Early December; NDA Submission for D-PLEX₁₀₀ On Track for Early 2026 Advancements in Discussions with Potential U.S. Partners Following Positive Phase 3 Trial Results Company Contin... Full story

Yahoo Finance • 10 months ago

PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"

PETACH TIKVA, Israel, Nov. 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company focused on improving surgical outcomes, today announced that D-PLEX₁₀₀, the company’s lead c... Full story

Yahoo Finance • 10 months ago

PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025

PETACH TIKVA, Israel, Oct. 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2... Full story

Yahoo Finance • 11 months ago

ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City

NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Metropolitan... Full story

Yahoo Finance • 11 months ago

PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress

PETACH TIKVA, Israel, Sept. 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Dr. Shmuel Sharoni will present t... Full story

Yahoo Finance • 11 months ago

PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference

PETACH TIKVA, Israel, Sept. 17, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that management will be presenting at... Full story

Yahoo Finance • 12 months ago

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

PETACH TIKVA, Israel, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that senior management will participat... Full story

Yahoo Finance • 12 months ago

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference

PETACH TIKVA, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Dalit Hazan, Deputy CEO, EVP R&D,... Full story

Yahoo Finance • last year

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Positive Phase 3 SHIELD II Trial Results -D-PLEX₁₀₀ successfully met its primary efficacy endpoint and demonstrated 58% reduction in SSI NDA submission expected in Q1 2026 Unveiled a Long-Acting GLP-1 Receptor Agonists Delivery Platform... Full story

Yahoo Finance • last year

PolyPid appoints Nurit Tweezer-Zaks as chief medical officer

* PolyPid  (NASDAQ:PYPD [https://seekingalpha.com/symbol/PYPD]) announced on Tuesday the appointment of Dr. Nurit Tweezer-Zaks as chief medical officer, effective as of August 18, 2025. * Tweezer-Zaks, who has served on PolyPid's board... Full story

Yahoo Finance • last year

PolyPid appoints Dr. Tweezer-Zaks as chief medical officer

PETACH TIKVA, Israel - PolyPid Ltd. (NASDAQ:PYPD), a clinical-stage biopharma company with a market capitalization of $32.92 million, announced Tuesday the appointment of Dr. Nurit Tweezer-Zaks as Chief Medical Officer, effective August 18... Full story

Yahoo Finance • last year

PolyPid stock price target lowered to $14 at JMP on warrant dilution

JMP Securities lowered its price target on PolyPid Ltd. (NASDAQ:PYPD) to $14 from $16 on Monday, while maintaining its Market Outperform rating on the stock. The micro-cap biotech company, currently valued at $37.4 million, has seen its... Full story

Yahoo Finance • last year

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

The Company Anticipates that with this Additional Funding, PolyPid’s Runway would be Extended beyond Anticipated U.S. Food and Drug Administration (FDA) Approval of D-PLEX ‚ ‚€ ‚€.The Company Recently Announced Successful Topline Results... Full story

Yahoo Finance • last year

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

D-PLEX100 successfully met the primary efficacy endpoint, with statistically significant results (p<0.005) in 798 patients with large abdominal surgery incisions.The trial successfully met all key secondary efficacy endpoints, including a... Full story